2 registrations that name lithothamnion as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
2US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT07501078
Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation
Phase 2
Muhammad N Aslam, MD
About 52 people
Starts Oct 2026 (estimated)
In plain words A Phase 2 study of lithothamnion in people 18 to 80, run by Muhammad N Aslam, MD. It plans to enroll about 52 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Ulcerative Colitis; Ileal Pouch.
Must be able to give written informed consent (or assent as appropriate)
Must have the following: UC with ileal pouch-anal anastomosis (IPAA) using a J-pouch without an ileostomy within the last nine months
For pre-menopausal women 18 years of age and older with intact reproductive organs, a negative pregnancy test is required within two weeks prior to the baseline visit.
The exclusion criteria are on the listing.
What it tests, as registered
Aquamin; Placebo
Registered summary
Ulcerative colitis (UC) is a disease that causes long-term inflammation in the digestive tract, and many people with this condition require surgery to remove the colon and create a new J-pouch for stool. Some patients develop a problem called pouchitis, where this pouch becomes inflamed. Current treatments are limited, and there are no known ways to prevent pouchitis from starting. This study is being done to find out if a natural mineral supplement called Aquamin® can help reduce inflammation and protect the gut lining in people with a J-pouch, and may reduce the risk of pouchitis. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05058638
Effectiveness of Aquamin® in Mitigating Halitosis
Phase 2
University of Michigan
About 25 people
Started Aug 15, 2022
In plain words A Phase 2 study of lithothamnion in people 18 to 99, run by University of Michigan. It plans to enroll about 25 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 99; healthy volunteers accepted. Conditions: Healthy; Halitosis.
Must be able to give written informed consent
Willing to follow study procedures of no eating, drinking, toothbrushing, smoking or using mouth rinse 60 minutes before study visits
Have stable oral health
Self-reported halitosis
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Aquamin
Registered summary
The purpose of this study is to assess whether Aquamin®, a multi-mineral natural product from red marine algae, can help reduce halitosis when taken for 90 days.